GlassScriptPhysician profile
Rita Goldvug
NPI 1447296421
$16,883.77
in general payments reported to CMS, 2019-2025
54 companies · $3,082 in 2025
The $3,082 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,296 · 2020: $1,378 · 2021: $2,346 · 2022: $2,339 · 2023: $2,413 · 2024: $3,030 · 2025: $3,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,421 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,420.70 |
| Education | $104.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,250.63 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,894.16 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,765.29 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $1,014.47 | 2019-2025 | Ztlido |
| Novo Nordisk INC | $988.17 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.55 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $776.63 | 2019-2022 | |
| Pfizer INC. | $760.80 | 2019-2025 | |
| Lilly USA, LLC | $503.46 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $501.75 | 2019-2021 | |
| Astellas Pharma US INC | $479.08 | 2019-2025 | Veozah |
| Aimmune Therapeutics, INC. | $443.97 | 2024-2025 | Zenpep, Vowst |
| Janssen Pharmaceuticals, INC | $421.04 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $362.66 | 2019-2024 | |
| Medtronic, INC. | $317.95 | 2023 | Corevalve Evolut R, Symplicity G3 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Goldvug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.